DexCom price target raised to $89 from $82 at Morgan Stanley

Morgan Stanley analyst Patrick Wood raised the firm’s price target on DexCom (DXCM) to $89 from $82 and keeps an Equal Weight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.